The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|October 17, 2017
Dr. Zandberg on Biomarker Development in Head and Neck Cancer
Author(s)Dan Zandberg, MD
Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.
Advertisement
Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.
Biomarkers are important for determining which immunotherapy regimen a patient should receive, says Zandberg. Currently, in head and neck cancer there has not been an identified biomarker to predict response to these therapies.
Advertisement
Related to this article
MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
3
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5